Carisma Therapeutics Secures Nasdaq Listing Approval

Carisma Therapeutics ( (CARM) ) has issued an announcement.

On June 10, 2025, Carisma Therapeutics received approval from a Nasdaq Hearings Panel to continue its listing on Nasdaq, with the listing being transferred to the Nasdaq Capital Market effective June 12, 2025. Despite previous non-compliance with Nasdaq’s listing rules, the company has been granted an extension until October 7, 2025, to meet specific conditions, including maintaining a minimum bid price and completing a strategic transaction, to ensure continued listing.

The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.

Spark’s Take on CARM Stock

According to Spark, TipRanks’ AI Analyst, CARM is a Neutral.

Carisma Therapeutics is significantly challenged financially, with negative profitability, unstable balance sheet, and poor cash flow. Technical analysis is slightly more favorable but still indicates risks with high RSI and below-average prices. The overall valuation is concerning with a negative P/E ratio. These factors collectively contribute to a low overall stock score.

To see Spark’s full report on CARM stock, click here.

More about Carisma Therapeutics

Carisma Therapeutics Inc. operates in the biotechnology industry, focusing on developing innovative therapies for various medical conditions. The company is primarily engaged in the research and development of therapeutic solutions, aiming to address unmet medical needs and improve patient outcomes.

Average Trading Volume: 13,107,447

Technical Sentiment Signal: Sell

Current Market Cap: $46.38M

See more insights into CARM stock on TipRanks’ Stock Analysis page.